{"entity":{"id":"nct06311721","kind":"trial","name":"A Study to Compare ABP 234 and Keytruda® (Pembrolizumab) in Participants With Advanced or Metastatic Non-squamous Non-Small Cell Lung Cancer","aka":[],"tldr":"A phase 3 trial of Pembrolizumab in non-small-cell lung cancer and small-cell lung cancer, run by Amgen, active and no longer recruiting.","summary":"A Study to Compare ABP 234 and Keytruda® (Pembrolizumab) in Participants With Advanced or Metastatic Non-squamous Non-Small Cell Lung Cancer is a phase 3 interventional study registered as NCT06311721 by Amgen, with 315 participants enrolled, started 2024-09-09 and due to reach its primary completion in 2028-01-10. Interventions recorded: ABP 234, Pembrolizumab (US), Pembrolizumab (EU). Conditions listed: Advanced or Metastatic Non-squamous Non-Small Cell Lung Cancer. No results are recorded here; the registry entry is the source.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06311721","url":"https://clinicaltrials.gov/study/NCT06311721"}],"tags":["ctgov-ingest"],"related":[],"cancers":["nsclc","sclc"],"sections":[],"technologies":["checkpoint-inhibitor"],"targets":[],"drugs":["pembrolizumab"],"companies":["amgen"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT06311721","phase":"3","setting":"A Randomized, Double-Blind Study to Compare Efficacy, Pharmacokinetics, Safety, and Immunogenicity Between ABP 234 and Keytruda® (Pembrolizumab) in Subjects With Advanced or Metastatic Non-squamous Non-Small Cell Lung Cancer","sponsor":"Amgen","participation":[{"nct":"NCT06311721","source":"https://clinicaltrials.gov/study/NCT06311721","fetchedAt":"2026-10-07T16:54:32.196Z","studySha256":"5d4dff5f7ec2bf03a2eabd7763e41ccf9d5fb96104cd212b2e401da14629aab1","overallStatus":"ACTIVE_NOT_RECRUITING","lastUpdatePosted":"2026-05-06","leadSponsor":"Amgen","collaboratorCount":0,"minimumAge":"18 Years","maximumAge":"99 Years","sex":"ALL","healthyVolunteers":false,"hasEligibility":true,"enrolment":315,"enrolmentType":"ACTUAL","siteCount":218,"recruitingSiteCount":0,"countries":["Argentina","Austria","Brazil","Bulgaria","Chile","France","Georgia","Germany","Italy","Japan","Malaysia","Peru","Philippines","Poland","Serbia","South Africa","South Korea","Spain","Taiwan","Thailand","Turkey (Türkiye)","United Kingdom","United States"]}],"started":"2024-09-09","startedType":"actual","enrolled":315,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct06311721/","neighbours":{"cancer":[{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"},{"id":"sclc","kind":"cancer","name":"Small-cell lung cancer","route":"/cancers/sclc/"}],"technology":[{"id":"checkpoint-inhibitor","kind":"technology","name":"Immune checkpoint inhibitors","route":"/technologies/checkpoint-inhibitor/"}],"drug":[{"id":"pembrolizumab","kind":"drug","name":"Pembrolizumab","route":"/drugs/pembrolizumab/"}],"company":[{"id":"amgen","kind":"company","name":"Amgen","route":"/companies/amgen/"}]}}